Methods of treating muscular wasting diseases using NF-KB activation inhibitors
Methods for treating muscular wasting diseases such as Duchenne muscular dystrophy are disclosed. Specifically, the methods include administering to a subject in need of treatment for a muscular wasting disease, an NF-κB activation inhibitor capable of blocking the activation of NF-κB.
1. A method of treating Duchenne muscular dystrophy in a subject, the method comprising administering to the subject an NF-κB activation inhibitor comprising:
a polypeptide having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 17.
2. The method of claim 1 , wherein the NF-κB activation inhibitor comprises the polypeptide having the amino acid sequence of SEQ ID NO: 17.
3. The method of claim 2 wherein the NF-κB activation inhibitor is administered to the subject in an amount of from about 0.001 mg/kg to about 100.0 mg/kg.
4. The method of claim 2 , wherein the NF-κB activation inhibitor is administered orally, parenterally, intraperitoneally, intravenously, intradermally, or transdermally.
5. The method of claim 1 , wherein the NF-κB activation inhibitor comprises the polypeptide having the amino acid sequence of SEQ ID NO: 1.
6. The method of claim 5 wherein the NF-κB activation inhibitor is administered to the subject in an amount of from about 0.001 mg/kg to about 100.0 mg/kg.
7. The method of claim 5 , wherein the NF-κB activation inhibitor is administered orally, parenterally, intraperitoneally, intravenously, intradermally, or transdermally.
8. The method of claim 1 wherein the NF-κB activation inhibitor is administered to the subject in an amount of from about 0.001 mg/kg to about 100.0 mg/kg.
9. The method of claim 1 , wherein the NF-κB activation inhibitor is administered orally, parenterally, intraperitoneally, intravenously, intradermally, or transdermally.